share_log

Citigroup Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $31

Benzinga ·  Aug 10 06:42  · Ratings

Citigroup analyst Samantha Semenkow maintains Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Buy and raises the price target from $27 to $31.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment